Hyderabad, June 7, 2024: Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced that Srinivas Sadu, the incumbent Managing Director (MD) and CEO, has been appointed as Executive Chairman and CEO of the company, effective June 10, 2024.
Srinivas Sadu, a seasoned professional with over two decades of rich experience, has been a key part of Gland’s journey. He assumed the role of MD and CEO on April 25, 2019, and has been instrumental in the company’s growth and success. His career with the company began in 2000, and he steadily rose through the ranks to become chief operating officer in 2011.
About Gland Pharma Limited (BSE: 543245, NSE: GLAND)
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com
